- Home
- CUBI vs SPRY Comparison
CUBI vs SPRY Comparison
Compare CUBI & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBI
- SPRY
- Stock Information
- Founded
- CUBI 1994
- SPRY 2015
- Country
- CUBI United States
- SPRY United States
- Employees
- CUBI N/A
- SPRY N/A
- Industry
- CUBI Major Banks
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- CUBI Finance
- SPRY Health Care
- Exchange
- CUBI Nasdaq
- SPRY Nasdaq
- Market Cap
- CUBI 1.6B
- SPRY 1.4B
- IPO Year
- CUBI 2012
- SPRY N/A
- Fundamental
- Price
- CUBI $51.95
- SPRY $15.69
- Analyst Decision
- CUBI Buy
- SPRY Strong Buy
- Analyst Count
- CUBI 10
- SPRY 4
- Target Price
- CUBI $65.67
- SPRY $28.75
- AVG Volume (30 Days)
- CUBI 180.3K
- SPRY 1.2M
- Earning Date
- CUBI 07-24-2025
- SPRY 08-05-2025
- Dividend Yield
- CUBI N/A
- SPRY N/A
- EPS Growth
- CUBI N/A
- SPRY N/A
- EPS
- CUBI 3.98
- SPRY N/A
- Revenue
- CUBI $591,500,000.00
- SPRY $97,122,000.00
- Revenue This Year
- CUBI $12.35
- SPRY N/A
- Revenue Next Year
- CUBI $10.10
- SPRY $140.40
- P/E Ratio
- CUBI $13.05
- SPRY N/A
- Revenue Growth
- CUBI N/A
- SPRY 971120.00
- 52 Week Low
- CUBI $40.75
- SPRY $7.55
- 52 Week High
- CUBI $68.49
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- CUBI 52.50
- SPRY 60.81
- Support Level
- CUBI $50.13
- SPRY $14.77
- Resistance Level
- CUBI $51.55
- SPRY $16.23
- Average True Range (ATR)
- CUBI 1.26
- SPRY 0.73
- MACD
- CUBI -0.12
- SPRY 0.12
- Stochastic Oscillator
- CUBI 50.84
- SPRY 84.68
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.